Carenostics, a New York-based healthcare AI startup focused on addressing undiagnosed and undertreated chronic diseases, raised $5 million in seed funding.
The round was led by M13, with participation from Greatpoint Ventures, Gaingels, and Kurt Hilzinger, Chairman of Humana, who also joined Carenostics' advisory board.
Founded in 2016, M13 is a venture capital firm based in Santa Monica, California. The firm seeks to invest in the technology, work, health, commerce, and money sectors.
Carenostics Use of Funds
The funding will be used to expand the company's presence in more health systems and chronic conditions.
Carenostics has developed an AI platform that identifies undiagnosed and undertreated chronic disease patients and prompts clinicians to intervene earlier within their current workflows. Carenostics tailors AI models to each health system using existing electronic health record (EHR) data and supports physicians across multiple diseases while prioritizing patient data privacy. Carenostics revolutionizes patient care through the application of clinically-oriented artificial intelligence, which identifies patients at risk for chronic diseases.
Carenostics has received awards from Bio-IT World, the National Science Foundation, and the Digital Health Hub Foundation, and their work has been accepted for publication in NeurIPS and AMGA.
Company: Carenostics, Inc.
Round: Seed Round
Funding Month: September 2023
Lead Investors: M13
Additional Investors: Greatpoint Ventures, Gaingels, and Kurt Hilzinger
Company Website: https://www.carenostics.com/
Software Category: Healthcare AI Solutions